Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

The conversation is about using bicalutamide, taken less frequently than daily, for hair loss treatment. The user is considering 50mg every 3 days or once a week and is asking for others' experiences.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

The conversation discusses Procapil, a treatment for hair loss containing Apigenin and Oleanolic acid. Users are sharing their experiences and asking if anyone has tried it.

PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.

The user tried topical dutasteride for 6 months without success and is considering Pyrilutamide as an anti-androgen treatment for hair loss. Other users suggest using 1% Pyrilutamide and combining it with topical dutasteride.

The post discusses a user's hair loss treatment involving Dutasteride 2.5 mg 5 times per week, Finasteride 1mg 4 times per week, RU58841 daily, and Minoxidil twice daily. A reply suggests that the combination is excessive, particularly the use of both Dutasteride and Finasteride, and labels it as a "chemical castration protocol".

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

The conversation discusses hair regrowth using dissolvable microneedles loaded with rapamycin and epigallocatechin gallate nanoparticles. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

A 31-year-old man shared his hair growth progress from July 2024 to March 2026 using oral finasteride (1mg) and minoxidil (2.5mg), with no significant side effects. He is considering switching treatments but is advised to continue with the current regimen due to its effectiveness.

The conversation discusses the use of RU58841 for hair loss, with one user sharing a one-month difference in their hair after using it. Users discuss where to buy RU58841, potential side effects including heart issues, and mixed opinions on its effectiveness, with some questioning the need for treatment based on the before and after pictures.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

A 20-year-old using 1 mg finasteride, 2 ml topical minoxidil, tretinoin, and microneedling for hair loss shows progress after three months, with thicker hair and temple regrowth. No side effects reported, and the user is considering switching to oral minoxidil.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

The user is on their 5th week of using pyrilutamide for hair loss without experiencing side effects and has noticed slight hair growth. They also use minoxidil with finasteride and dutasteride as part of their treatment regimen.

The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

The user reports that their hair loss treatment with oral minoxidil, dutasteride, finasteride, topical minoxidil, ketoconazole shampoo, and microneedling has plateaued, with no significant additional regrowth. They have stopped using creatine to simplify their regimen and are relieved with the current state compared to before treatment.

The user experienced sexual side effects after starting finasteride and later switched to dutasteride, noticing hormonal changes. They are considering using P5P and possibly aromatase inhibitors to manage high prolactin and estradiol levels.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

The user's experience of using Finasteride 5mg and Aldactone 50mg to treat Female Pattern Hair Loss, as well as their use of PRP injections for further hair growth.

A 26-year-old is considering switching from a regimen of minoxidil, finasteride, and RU58841 to possibly include pyrilutamide due to insufficient results in slowing hair loss. They are seeking advice on whether to add pyrilutamide or replace RU58841 with it, considering cost and effectiveness.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

User seeks KX-826 anti-androgen product and asks for purchase suggestions and experiences. Dave-8D recommends buying powder from the same website and making a topical solution, mentioning possible high dosage from Minoxidil max causing side effects.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

The user is using finasteride and minoxidil for hair loss but is looking for new treatments. Pyrilutamide and GT20029 are potential future treatments, with Pyrilutamide expected next year and GT20029 possibly by 2027.